Paraoxonase-1 polymorphisms and cerebral ischemic stroke: a pilot study in mexican patients

Caracterización polimórfica de la paraoxonasa-1 en el infarto cerebral aterotrombótico de una poblacion mexicana: estudio piloto

María Fernanda Martínez-Salazar¹, María de la Luz Soriano-Martínez², Alina Juantorena-Ugás³, Damianys Almenares-López³, Petra Yescas³, Marie-Catherine Boll³ and Antonio Monroy-Noyola³

1 Laboratorio de Bioquímica, Facultad de Ciencias del Deporte, Universidad Autónoma del Estado de Morelos. Cuernavaca, México.
2 Laboratorio de Neuroprotección, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos. Cuernavaca, México.
3 División Ciencias Agropecuarias e Ingenierías, Universidad Popular de la Chontalpa, Cárdenas, Tabasco, México.
4 Departamento de Neurogenética, Instituto Nacional de Neurología y Neurocirugía, M.V.S. Ciudad de México. Mexico.
5 Investigación Clínica, Instituto Nacional de Neurología y Neurocirugía, M.V.S. Ciudad de México México.

Martínez-Salazar MF, Soriano-Martínez MDLM, Juantorena-Ugas A, Almenares-Lopez D, Yescas P, Boll MC and Monroy-Noyola A. Paraoxonase-1 polymorphisms and cerebral ischemic stroke: a pilot study in mexican patients. Colomb Med (Cali). 2018; 49(3): 223-27. DOI: 10.25100/cm.v49i3.2217

© 2018 Universidad del Valle. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided that the original author and the source are credited.

Abstract

Background: The serum paraoxonase-1 (PON1) associated to HDL presents two common polymorphisms in the positions 192 and 55. These polymorphisms are considered determinant of the capacity of HDL to protect LDL from their oxidative modification. In this context, the PON1 genotype has been associated with cardiovascular diseases, including stroke.

Objective: To determine the allelic and genotypic frequencies of PON1 L55M and Q192R as well as the enzymatic activities of PON1 in subjects with and without atherothrombotic stroke.

Methods: There were included 28 people with atherothrombotic stroke and 29 without stroke. The genotyping was carried out by PCR-RFLP and the phenotyping by measurement of the activities of paraoxonase and arylesterase in serum.

Results: For the polymorphism Q192R, the allelic frequencies (Q/R) were 0.46/0.54 and 0.48/0.52 (p = 0.843) for the control group and the group with stroke, respectively. While for the polymorphism L55M, the allelic frequencies (L/M) were 0.81/0.19 for the control group, and 0.78/0.22 for the group with stroke (p = 0.610). The activity levels of paraoxonase were not significantly different between the control and stroke groups (450 vs. 348 U/L/mL, p = 0.093) While the activity levels of arylesterase were significantly different between the studied groups (90 vs. 70 U/L/mL, p = 0.001); however, upon adjustment by multiple linear regression, it was not longer significant.

Conclusion: The polymorphisms Q192R and L55M, and the paraoxonase activity of PON1 are not risk factors for atherothrombotic stroke according to the results of this study.

Resumen

Introducción: La paraoxonasa-1 (PON1) sérica asociada a las HDL presenta dos polimorfismos comunes en las posiciones 192 y 55. Estos polimorfismos se consideran determinantes para la capacidad de las HDL de proteger a las LDL de su modificación oxidativa. En este contexto, el genotipo de PON1 se ha asociado con enfermedades cerebrovasculares, que incluyen el infarto cerebral.

Objetivo: Determinar las frecuencias alélicas y genotípicas de PON1-L55M y PON1-Q192R, así como las actividades enzimáticas de PON1 en sujetos con y sin infarto cerebral aterotrombótico.

Métodos: Se incluyeron 28 personas con infarto cerebral aterotrombótico y 29 sin infarto. Las genotipificaciones se realizaron mediante PCR-RFLP y las fenotipificaciones mediante la medición de las actividades paraoxonasa y arilesterasa en suero.

Resultados: Para el polimorfismo Q192R, las frecuencias alélicas (Q/R) fueron 0.46/0.54 y 0.48/0.52 (p = 0.843) para el grupo control y el grupo con infarto, respectivamente. Mientras que para el polimorfismo L55M, las frecuencias alélicas (L/M) fueron 0.81/0.19 para el grupo control y 0.78/0.22 para el grupo con infarto (p = 0.610). Los niveles de actividad paraoxonasa no fueron significativamente diferentes entre los grupos control y con infarto (450 vs. 348 U/L/mL, p = 0.093). Mientras que los niveles de actividad arilesterasa fueron significativamente diferentes entre los grupos estudiados (90 vs. 70 U/L/mL, p = 0.001), sin embargo, al ajustar por regresión lineal múltiple, dejó de ser significativa.

Conclusion: Los polimorfismos Q192R y L55M, y la actividad paraoxonasa de la PON1 no son factores de riesgo para el infarto cerebral aterotrombótico en este estudio.

Corresponding author: Antonio Monroy-Noyola. PhD. Laboratorio de Neuroprotección y Bioquímica Clínica Facultad de Farmacia, Universidad Autónoma del Estado de Morelos Av. Universidad 1001 Col. Chamilpa. C.P. 62210 Cuernavaca Morelos. Tel +52 777 329 700 ext. 7089. E- mail: amonroy@auem.mx
Introduction

The ischemic cerebrovascular disease (CVD) or cerebral stroke, is caused by the interruption of cerebral blood flow caused by a thrombus promoted by atherosclerosis or cardioembolism.1 Atherothrombotic cerebral infarction is the most common subtype of cerebral infarctions, having an approximate frequency of 37% being the clinical consequence of the atheromatous disease. Multiple factors induce atherogenesis, mainly oxidized low density lipoproteins (ox-LDL), which trigger an immune response in the wall of the vessel participating in the development of atherosclerosis.2 LDL oxidation degree depends on the balance of oxidants/antioxidants agents and the existing LDL concentration.3 On the other hand, it is known that high density lipoproteins (HDL) have an anti-atherosclerotic role, since they metabolize ox-LDL in the arterial wall, transporting them to the liver for their elimination.4 This capacity of the HDL is due to the association of enzymes such as paraoxonase-1 (PON1) and acetyhydrolase of the platelet activating factor (PAF-AH) which decrease LDL peroxidation.5,6

PON1 is a 355 amino acids enzyme, synthesized by the liver and secreted into the bloodstream, where it is associated with HDL.8,9 PON1 presents a polymorphism at position 192 of the coding region, that is characterized by a substitution of a glutamine (Q) by an arginine (R) and another one at position 55, where there is a change from a leucine (L) to a methionine (M).10 Q192R polymorphism affects the ability to hydrolyze organophosphorus compounds such as paraoxon.11 The two Q192R polymorphism allozymes have different affinities and catalytic activities towards several substrates.12 These polymorphisms also modify PON1 ability to protect LDLS from oxidation.

From the observed effect of common polymorphisms of PON1 on the protection by HDL against the oxidative modification of LDL, it has been suggested that homozygotes for Q and for M of PON1 could be less susceptible of developing atherosclerotic diseases, and homozygotes for R and L could be more prone to develop those diseases.13 The frequent association of RR genotype of PON1 192 with the risk of cardiovascular diseases reflects a diminished efficiency in the metabolism of oxidized lipids and/or less stability of this alloenzyme compared with QQ genotype.14 In this context, PON1 Q192R and PON1 L55M polymorphisms, as well as enzymatic activity of PON1, have been considered a tool that can contribute to the risk estimation of atheromatous diseases. Thus, the aim of this study was to investigate the relationship between PON1 genetic polymorphisms and ischemic CVD of atherosclerotic etiology.

Materials and Methods

A study of cases and controls was conducted by the National Institute of Neurology and Neurosurgery (INNN) in Mexico City, during the year 2005. The participants or relatives signed an informed consent and answered a questionnaire (demographic, clinical and life styles data) and provided a venous blood sample for biochemical and molecular analysis. The case group were hospitalized subjects between 35 and 85 years of age who passed the established tests for blood donation in the same hospital. The study was approved by the INNN Bioethics Committee (No. 67/01).

For biochemical assays the Hitachi 912 autoanalyzer (Roche, Basel, Switzerland) was used. The total serum cholesterol (TC) and triglycerides (TG) determination were carried out with CHOD-PAP, HDL-C with HDL-C plus third generation and LDL-C with LDL-C second generation (Roche Diagnostic).

Paraoxonase activity was determined in serum by modifying the Eckerson method.15 The enzyme-substrate reaction was initiated by the addition of 20 µL of serum plus 980 µL of buffer pH 8 (Tris 10 mM, 1 mM CaCl2, 2.6 M NaCl µL, 1 mM of paraoxon). The rate of hydrolysis was determined with a UV-VIS spectrophotometer (Varian Cary 50, Varian Inc., Palo Alto, CA) by measuring the hydrolysis product (p-nitrophenol) at a wavelength of 412 nm. Increases in A412 continued for 5 min (a molar extinction coefficient of 17,100 M⁻¹ cm⁻¹ was used). For the arilesterase activity, 2.995 µL of phenyl acetate (1 mM) was used as a substrate in a pH 8 buffer (Tris 10 mM CaCl, 1 mM) and 5 µL of serum. The rate of product (phenol) at 270 nm wavelength, monitoring it for 3 min and registering the value before and after the incubation was obtained. Absorbance was adjusted based on the molar extinction coefficient 1,310 M⁻¹ cm⁻¹.15

To determine PON1-Q192R and PON1-L55M genetic polymorphisms, genomic DNA was extracted from whole blood using a commercial Kit (AquapureTM Genomic DNA kit, Bio-rad Laboratories, Hercules, CA). The identification of PON1 genotypes was carried out by PCR-RFLP,17 with further digestion of the amplified products with BspPI restriction enzymes (Fermentas) for PON1-Q192R and HinIII (Fermentas) for PON1-L55M. The digested fragments were separated by electrophoresis and visualized in polyacrylamide gels at 7.5% and 20% for PON1-Q192R and for PON1-L55M (two fragments of 126 and 44 pb) and PON1-Q192R (two fragments of 66 and 33 pb), respectively. The laboratory personnel carried out the samples genotyping in a blind test which included control samples (identified previously by sequencing) and the experimental samples validation. The concordance with the control samples was 100%.

The categorical variables were compared by using Chi square test. The variables with normal distribution were compared by a Students-t or ANOVA. Those non normal variables were analyzed with the U test of Mann-Whitney and were further transformed to logarithmic values to carry out the regression tests. The variables were evaluated in a simple linear regression, those with a p-value of less than or equal to 0.1 were included in a saturated model of multiple linear regression, eliminating those that lost statistical significance. Age and sex were maintained for being potentially confounding. The data were analyzed by using the SPSS’ statistical program version 13, with a statistical significance of 0.05.

Results

The present study included 28 cases of atherothrombotic cerebral infarction and 29 controls. Table 1 show that age, sex and alcohol and tobacco consumption were different between cases and controls. The clinical parameters of BMI, serum lipids (with the exception of triglycerides) and hypercholesterolemia were similar between both groups.
Triglycerides (TG), HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C), the value of significance was for U-Mann Whitney. Total-C: total cholesterol.

The genotypes frequencies of Q192R and L55M polymorphisms of PON1 (Table 1) were not statistically different ($p = 0.786$ and $p = 0.282$, respectively) between the control and case groups. Subsequently, the allelic distributions of Q/R and L/M for the Q192R and L55M polymorphisms respectively, were compared and no differences were found.

The paraoxonase activity of PON1 was greater in the control group (450.27 UI/mL) than in the case group (348.35 UI/mL), although the difference was not statistically significant ($p = 0.093$). This was similar to the arylesterase activity of PON1, which was greater in the control group (89.96 IU/mL) than in the case group (69.63 IU/mL), being this difference statistically significant ($p = 0.001$) (Fig. 1).

In the simple regression analysis for paraoxonase activity (Table 2), it was observed that such activity was explained by serum triglyceride, by arylesterase, by both polymorphisms and by the (cases vs controls). In the multiple regression model, it was demonstrated that age, arylesterase and Q192R polymorphism, were the factors that determined in a significant and independent way paraoxonase activity variation in 78.5%. It was also found that diagnosis ($p = 0.85$ in the saturated model, data not shown), did not influence paraoxonase activity of the subjects.

For arylesterase activity (Table 3), in the simple regression analysis, the variables of diagnosis, age, total cholesterol, alcohol consumption and Q192R polymorphism were related with the activity. In the multiple regression analysis, age, alcohol consumption and total cholesterol (the latter with a marginal significance) determined in a significant and independent way the arylesterase activity variation, although they only explained it in a 27.6%. The statistical difference obtained from the arylesterase activity between control and case groups was not longer significant upon adjustment during the multiple linear regression.

**Discussion**

In this research, the analysis of the allelic distribution and the corresponding genotypes for Q192R and L55M of the PON1 polymorphisms showed an absence of risk due to these genetic factors for atherothrombotic CVD, similar to the ones found in other populations, even with a larger sample, for risk of coronary heart disease and cerebral infarction. However, there are still conflicting results, since in a meta-analysis, it was found that there is a small increase in suffering cerebral infarction in people presenting the R allele of Q192R polymorphism. An optimal analysis of the relationship between PON1 polymorphisms and CVD in our population could be carried out, increasing the number of individuals in the control and case groups.

---

**Table 1. Clinical and anthropometric characteristics and allele/genotype frequencies of the study groups.**

|                  | Controls (n= 28) | Cases (n= 29) | $p^*$ |
|------------------|-----------------|---------------|-------|
| **Age (years)**  | 48 (43-54.5)    | 61 (53-71.5)  | 0.001 |
| **Male/female**  | 21/8            | 13/17         | 0.024 |
| **BMI (kg/m$^2$)** | 27.12±0.80      | 27.77±0.78    | 0.568 |
| **TG (mg/dL)**   | 31.02           | 23.41         | 0.073 |
| **Total-C (mg/dL)** | 213.62±10.06  | 191.98±9.05   | 0.116 |
| **HDL-C (mg/dL)** | 31.02           | 23.41         | 0.073 |
| **LDL-C (mg/dL)** | 124.4±9.97      | 124.2±6.31    | 0.987 |
| **HTA, n (%)**   | 2 (6.9)         | 16 (55.2)     | $< 0.001$ |
| **DM, n (%)**    | 0 (0.0)         | 9 (31.0)      | 0.001 |
| **Tobacco consumption, n (%)** | 2 (6.9) | 8 (27.6) | 0.037 |
| **Alcohol consumption, n (%)** | 0 (0.0) | 8 (28.6) | 0.002 |

**Table 1.** Clinical and anthropometric characteristics and allele/genotype frequencies of the study groups.

**Figure 1.** Paraoxonase and arylesterase activities of serum PON1. Bars represent the confidence interval at 95%; (a) paraoxonase activity, $p = 0.093$ and (b) arylesterase activity, $p = 0.001$, by student $t$ test.
Regarding PON1 activity, this study demonstrated that control subjects and the subjects with infarction had no differences in the paraoxonase and arylesterase activities, thus, the level of activity of this enzyme did not represent a risk for the atherothrombotic infarction. The linear regression analysis allowed us to know that age is one of the factors which have influence in the levels of the paraoxonase and arylesterase activities of PON1. While alcohol consumption and cholesterol levels were factors which also had an independent effect regardless of age on the arylesterase activity, suggests to consider such variables in future studies in order to confirm its effect on PON activity.

The arylesterase activity has been used as a measure of PON1 level. Therefore, the homogeneous distribution that was found in the arylesterase activities among QQ, QR and RR genotypes suggests similar levels of this enzyme. Differences found in paraoxonase activity were not dependent on PON1 level but on the Q192R genotype, as it was proposed when the polymorphism was discovered for the first time.

Comparing our control group with the reference group in a study carried out in the United Kingdom, we found a notable difference between paraoxonase activities (450.27 vs. 214.6 IU/mL) where Mexican subjects presented the higher activity. After grouping by genotype the same comparison, the paraoxonase activities in the control subjects QQ, QR, and RR (122.3, 463.9 and 695.1 IU/mL, respectively) were also higher than in the respective genotype (116, 226, and 396.4 UI/mL) of the control group in the United Kingdom (the taken data were the reported medians). It is possible that such differences are explained by a different exposure among both populations such as environmental factors and other factors which regulate the PON1 expression, stimulate or inhibit its activity. A comparison must be done between both control groups.

One of the limitations of this work was the samples size, as well as the fact that it was not possible to assess the effect of other variables such as food habits, drug therapies or comorbid diseases that could influence arylesterase and paraoxonase activities of PON-1.

**Conclusion**

In this study where Mexican subjects were included, Q192R and L55M polymorphisms, paraoxonase and arilesterase activities from PON1 are not risk factors for atherothrombotic cerebral infarction.

**Acknowledgements:**

Dr. Bert the Du and the Dr. Dragomir Draganov of the Department of Pharmacology of the University of Michigan for its advice on measurements of PON-1.

**Funding Statement**

CONACYT scholarship with Registration number 188830. Stimulus granted 2003 / 2005 by The Miguel Alemán Foundation.

**Conflict of interest:**

The authors state that there are no conflicts of interest.

**References**

1. Bogousslavsky J, Castillo V. Clasificación de la enfermedad vascular cerebral. En: Barinagarrementeria F, Cantú C. (ed). Enfermedad Vascular Cerebral. McGraw-Hill Interamericana: México; 1998 p.1.

2. Mohr J. Lacunes. Stroke. 1982; 13: 3-11.

3. Berliner J, Navab M, Fogelman A, Frank S, Demer L, Edwards P, et al. Atherosclerosis: basic mechanisms oxidation, inflammation, and genetics. Circulation. 1995; 91: 2488-96.
4. Navab M, Berliner JA, Watson AD, Hama SY, Territo C, Lusis J. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996;16: 831- 42.

5. Parthasary S, Barnett J, Fong LG. High density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochem Biophys Acta. 1990; 1044: 275-83.

6. Smith L. Review of progress in sterol oxidations. Lipids. 1996; 31: 453-87.

7. Watson AD, Leitinger N, Navab M, Faull KF, Hörkkö S, Witztum JL, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997; 272: 13597-607.

8. La Du B. Structural and functional diversity of paraoxonases. Nat Med. 1996; 2: 1186-87.

9. Primo-Parma L, Sorenson C, Teiber J, La Du B. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996; 33:498-509.

10. Adkins S, Gan KN, Mody M, La Du B. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993; 52:598-608.

11. Costa LG, Li WF, Richter J, Shih DM, Lusis A, Furlong C. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact. 1999; 119-120: 429-38.

12. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du B. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000; 28:1335-42.

13. Mackness B, Mackness M, Arrol S, Turkie, W, Durrington P. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998; 423:57-60.

14. Draganov D, La Du B. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's Arch Pharmacol. 2004; 369:78-88.

15. Eckerson H, Wyte M, La Du B. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983; 35:1126-38.

16. Gan KN, Smolen A, Eckerson HW, La Du B. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1992; 19: 100-106.

17. Humbert R, Adler D, Distèche M, Hassett C, Omiecinski J, Furlong C. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993; 3:73-6.

18. Mackness B, Davies GK, Turkie W, Lee E, Roberts H, Hill E, et al. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol. 2001; 21:1451-57.

19. Huang Q, Liu Y-h, Yang Q-d, Xiao B, Ge L, Zhang N, et al. Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population. Neurol Res. 2006; 28: 549-54.

20. Dahabreh I, Itsios G, Kent D, Trikalinos T. Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis. Gen Med. 2010; 12: 606-15.

21. Nevin N, Zambon A, Furlong C, Richter J, Humbert R, Hokanson J, et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol. 1996; 16:1243-49.